RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026)

RetinalGenix Technologies (RTGN) reported Non-Current Debt of $49000.0 for Q1 2026, little changed sequentially from $49000.0 in Q4 2025.

RetinalGenix Technologies (RTGN) Non-Current Debt (2022 - 2026) Analysis & Trends

RetinalGenix Technologies (RTGN) has 4 years of Non-Current Debt data on file, last reported at $49000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $49000.0; the trailing twelve-month figure through Mar 2026 stood at $49000.0 (changed N/A YoY), and the FY2025 full-year result was $49000.0, changed N/A from the prior year.
  • Non-Current Debt steadied at $49000.0 in Q1 2026, from $49000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $49000.0 in Q4 2022 to a low of $49000.0 in Q4 2022.
  • A 4-year average of $49000.0 and a median of $49000.0 in 2022 frame the typical range for Non-Current Debt.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 29.64 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 14.22 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 26.17 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 10.99 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn 598.50 Mn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 10.13 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn - 3.18 Bn
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 8.07 Bn
10 RetinalGenix Technologies 75.02 Mn 75.02 Mn - 49,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 49,000.00
Dec 31, 2025 49,000.00
Sep 30, 2023 49,000.00
Dec 31, 2022 49,000.00